Two patients with rituximab associated low gammaglobulin levels and relapsed covid-19 infections treated with convalescent plasma.
Transfus Apher Sci
; 60(3): 103104, 2021 Jun.
Article
in English
| MEDLINE | ID: covidwho-1104306
ABSTRACT
Patients with haematological malignancies are considered to be a risk group for developing severe Coronavirus disease (Covid-19). Because of the limitations of therapeutic options, the development of new treatment strategies is mandatory, such as convalescent plasma (CP). Herein we report the use of CP therapy as an off-label indication in two lymphoma patients with relapsed COVID-19 in the setting of low gammaglobulin levels because of previous rituximab chemo-immunotherapy. Both were PCR positive for SARS-CoV-2 but had an absence of antibodies to the virus more than one month later of symptoms initiation. They developed important respiratory and neurological complications. After CP infusion, neutralising antibodies were detected and viral load dissapeared in both patients leading to clinical improvement with no more Covid-19 relapse.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Gamma-Globulins
/
Rituximab
/
COVID-19
Type of study:
Case report
/
Prognostic study
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Transfus Apher Sci
Journal subject:
Hematology
Year:
2021
Document Type:
Article
Affiliation country:
J.transci.2021.103104
Similar
MEDLINE
...
LILACS
LIS